Plain-English translation of NCT07101744 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new combination treatment made up of three medications—Iparomlimab, Tuvonralimab, and Nimotuzumab—for people with nasopharyngeal cancer (a cancer in the back of the nose and throat) that has come back or spread after their first round of treatment failed. The study wants to see if this medication combination can help shrink tumors and control the cancer better than what's available now, while being safe enough for patients to tolerate.
Nasopharyngeal cancer often comes back or spreads despite initial treatment, and patients need better options. This new treatment uses a combination approach to boost the immune system and target cancer cells differently, offering hope for people who haven't had success with standard first-line therapies.
You likely qualify if…
You likely don't qualify if…
You would receive the medication combination as an injection every 3 weeks, continuing for up to one year or until your cancer progresses or side effects become too difficult to manage. You would attend regular clinic visits for blood tests, imaging scans, and check-ups to monitor how well the treatment is working and how you are tolerating it. You may also need to provide a tumor tissue sample at the beginning for genetic testing to help researchers understand your cancer better.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
China